Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q1 2025/26 Earnings Presentation
9 slides from Coloplast A/s Class B's earnings presentation, Feb 6, 2026
Slide 1: Making life easier
Conference call presentation Q1 2025/26 Making life easier Impact4: Setting the standard of care at scale Tomoko | User, Voice & Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Q1 2025/26 financial result
Q1 2025/26 financial result Organic EBIT growth* ROIC growth in constant currencies 6% 3% * * 15% ** *before special items and in constant currencies Dorote | User, Continence Care **after tax and before special items. 3
Slide 4: Q1 organic growth of 6% driven by Chronic Care and Interventional Urology
Q1 organic growth of 6% driven by the Chronic Care and Interventional Urology, with limited growth in Wound & Tissue Repair Q1 2025/26 revenue by business area Q1 2025/26 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share o
Slide 5: Q1 reported revenue grew 0% with impact from Skin Care divestment and currencies
Q1 reported revenue grew 0% with ~1%-pts negative impact from the Skin Care divestment and ~4%-pts negative impact from currencies Q1 2025/26 Revenue development (mDKK) Q1 2025/26 highlights • Reported revenue increased by DKK 17 million or 0% vs. last year. • Organic growth was 6% or DKK 393 millio
Slide 6: EBIT margin of 26% in Q1, driven by increased admin. and R&D costs
EBIT margin of 26%1 in Q1, driven by an increased level of admin. and R&D costs vs. last year, including negative impact from currencies Q1 2025/26 EBIT margin development before special items (%) Q1 2025/26 highlights • Gross margin was 67%, compared to 68% last year. • Negative impact from ramp-up
Slide 7: FCF was DKK 1,821 million in Q1 2025/26, with FCF-to-sales ratio of 26%
FCF was DKK 1,821 million in Q1 2025/26, with a FCF-to-sales ratio of 26%, driven by lower net financial items FCF development1 Q1 2025/26 highlights • Free cash flow for Q1 2025/26 was an inflow of DKK 1,821 million, 93 compared to an inflow of DKK 1,874 million last year, or a 3% decrease. 84 81 8
Slide 8: FY 2025/26: Organic growth of ~7% and EBIT growth of ~7%
FY 2025/26: Organic growth of ~7% and EBIT growth* of ~7%. ROIC** expected around 16%, compared to 15% adjusted last year Organic revenue growth Around 7% Reported revenue growth in DKK Around 4% EBIT growth* in constant currencies Around 7% ROIC** Around 16% Capex-to-sales ratio Around 5% Effective
Slide 9: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding